EIP
SWTX

Ellis Investment Partners’s SpringWorks Therapeutics SWTX Stock Holding History

Ellis Investment Partners’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-100
Closed -$2K – 677
2022
Q3 		$2K Hold
100
– – ﹤0.01% 732
2022
Q2 		$2K Buy
+100
New +$3.66K ﹤0.01% 735

Other funds holding SWTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Ellis Investment Partners's SWTX Position: Q4 2022 in Review

Ellis Investment Partners sold out of SpringWorks Therapeutics (SWTX) in Q4 2022, closing a stake of 100 shares — an estimated $2K sold.

Ellis Investment Partners first reported a position in SWTX in Q2 2022 and held it in 2 quarters. The position peaked at $2K in Q3 2022. 137 funds tracked by Wall St. Rank hold SWTX as of Q4 2022.

  • Ellis Investment Partners reported no remaining SpringWorks Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Ellis Investment Partners sold 100 SpringWorks Therapeutics shares in Q4 2022, an estimated $2K.
  • Ellis Investment Partners first reported a position in SpringWorks Therapeutics in Q2 2022 and held it in 2 quarters.
  • Ellis Investment Partners's SpringWorks Therapeutics position peaked at $2K in Q3 2022.
  • 137 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q4 2022.

Based on Ellis Investment Partners's 13F filing for Q4 2022, filed 31 Jan 2023.